PubMed Health⌕ Search

Biomedical subjects

M T Zarrabeitia

Publications and source records attributed to M T Zarrabeitia.

30 records · Page 2Linked to original sources

Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells.

The lymphokine interleukin-4 (IL-4) is an important lymphocyte growth factor, and it also has a modulatory role on hematopoiesis. It was recently reported that IL-4 has an inhibitory effect on bone resorption in vitro, but the underlying mechanisms are not well known. We studied its effects on the formation of osteoclast-like cells in mouse bone marrow cultures and in cocultures of spleen cells and stromal cells. The addition of recombinant mouse IL-4 (0.01-10 ng/ml) induced a marked dose-dependent inhibition on the formation of TRAP-positive multinucleated cells (MNC) in bone marrow cultures. The effect was blocked by anti-IL-4 antibodies and was not related to a decreased production of IL-6. The inhibitory effect required the presence of IL-4 during the second half of the culture period. Time course experiments showed that IL-4 impaired the formation of osteoclast-like cells rather than inducing the disappearance of previously formed cells. This inhibitory effect was associated with increased numbers of esterase-positive cells. Moderately high doses of IL-4 (1-10 ng/ml) also induced the formation of abundant macrophage polykaryons that did not form resorption pits. IL-4 had a similar inhibitory effect on the formation of osteoclast-like cells in cocultures of mouse spleen cells and stromal cells. Our results suggest that IL-4 acts on uncommitted macrophage-osteoclast precursors, inducing a preferential differentiation toward the macrophage lineage and thus decreasing the formation of osteoclast-like cells.

Animals↗

Effects of interleukin-4 on human osteoblast-like cells.

Interleukin-4 (IL-4) modulates the activity of a variety of lymphoid, hemopoietic and mesenchymal cells, but little is known about its influence on bone cells. We have studied the effects of IL-4 on the human osteoblast-like cell line MG63. IL-4 (0.1-50 ng/ml) inhibited cell proliferation. The effect did not depend on cell density, but it was more marked in serum-free cultures than in the presence of serum. IL-4 also induced a dose-dependent increase in the expression of alkaline phosphatase stimulated by 1,25-dihydroxyvitamin D3, a marker of differentiated osteoblast activity. However, IL-4 did not modify the secretion of interleukin-6 or tumor necrosis factor. These results suggest that interleukin-4 may play a role as a modulator of osteoblast activity.

Alkaline Phosphatase↗

Vitamin D therapy modulates cytokine secretion in patients with renal failure.

In studies in vitro calcitriol (1,25-dihydroxyvitamin D3) inhibits lymphocyte proliferation and modulates several monocyte functions, including the secretion of prostaglandins and monokines. However its effects on monokine production in vivo are not known. Therefore we studied the secretion of interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF) by peripheral blood mononuclear cells (PBMC) from 7 patients on periodic hemodialysis, before and after oral treatment with calcitriol (0.5 microgram daily) for 1 month. Calcitriol therapy resulted in significant increases in the phorbol myristate acetate (PMA)-induced secretion of IL-1 and IL-6 (p = 0.04 and 0.03, respectively). This was a transient effect, observable by day 7 of therapy, but no longer evident by day 30. However, calcitriol induced a progressive reduction of TNF secretion (down to 53% of control values by day 30, p = 0.02). There were no correlations between the individual changes in calcium/PTH and cytokine release. These results show that doses of calcitriol within the therapeutic range induce marked changes in cytokine secretion by PBMC from uremic patients.

Adult↗

Effect of calcitriol on the secretion of prostaglandin E2, interleukin 1, and tumor necrosis factor alpha by human monocytes.

Cells of the monocyte/macrophage lineage express specific receptors for calcitriol (1,25-dihydroxyvitamin D3) and secrete prostaglandins and several cytokines with potent effects on bone metabolism. The aim of this study was to determine the effect of calcitriol on the secretion of prostaglandin E2 (PGE2), interleukin-1 (IL-1), and tumor necrosis factor (TNF alpha). Monocyte-enriched peripheral blood mononuclear cells (PBMC) from healthy subjects were cultured in the presence or absence of calcitriol (10(-11)-10(-7) M) and several stimulating agents. After 24 h, PGE2, IL-1, and TNF alpha were measured in the culture supernatants or lysates with specific immunoassays. Calcitriol induced a biphasic effect on PGE2 production by unstimulated cells and increased PGE2 synthesis by cells stimulated with either endotoxin or tau-interferon (IFN-tau). On the other hand, calcitriol inhibited the production of TNF alpha by monocytes stimulated with either IFN-tau or phorbol esters. This effect was not prevented by the addition of indomethacin, IL-1, or IL-2. Under the conditions used, we observed no effect of calcitriol on IL-1 alpha or IL-1 beta production. These results indicate that calcitriol induces in vitro marked changes in the secretion of monocyte products with known activity on bone cells. Further studies are needed to elucidate whether some effects of calcitriol on bone metabolism are mediated by the interaction of the sterol with cells of the immune system.

Calcitriol↗

Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer.

Patients with lung cancer (LC) have a reduced T-cell proliferative response to phytohemagglutinin (PHA) compared with that of healthy individuals. This decreased response is a result of an inhibitory effect exerted by the monocytes as evidenced by: (1) a restoration to normal levels of the response to PHA when the peripheral blood mononuclear cells were depleted of adherent cells (AD) and (2) a dose-dependent inhibition of the response to PHA when the nonadherent cell population was co-cultured with increasing numbers of autologous AD cells. The addition of indomethacin to the cultures resulted in only a partial restoration of the response to PHA. Monocyte production of interleukin-1 from patients with LC in response to lipopolysaccharide was normal. These findings support the hypothesis that the AD cell population plays a major role in the low T-cell proliferative response to PHA in patients with LC. This suppressor effect is partially mediated by the prostaglandins released by the monocytes.

Adenocarcinoma↗

Cytokine production by peripheral blood cells in postmenopausal osteoporosis.

It has been suggested that the release of cytokines with bone-resorbing activity from cells of the immune system might have a role in the pathogenesis of osteoporosis. We measured the secretion of the bone-resorbing products tumor necrosis factor, interleukin 1 beta and PGE2 by peripheral blood mononuclear cells from seven healthy postmenopausal women and 12 patients with postmenopausal osteoporosis. No differences were observed between both groups either in unstimulated cultures or in cultures activated with calcitriol, endotoxin or phorbol esters. These results give no support for a role of peripheral blood immune cells in postmenopausal bone loss.

Aged↗

Lack of effect of human parathyroid hormone and calcitonin on cytokine and prostaglandin secretion by blood mononuclear cells.

The interactions between the endocrine and immune systems are complex and not well understood. Several data suggest the existence of a particular relation between bone and immune cells. Cells of the immune system express specific receptors for various calciotropic hormones, including parathyroid hormone (PTH) and calcitonin. In addition, several drugs used in the therapy of osteoporosis have been reported to modify the release of bone-active substances by immune cells. These facts prompted us to study in vitro the possible influence of PTH and calcitonin on the secretion of interleukin-1 (IL-1), tumor necrosis factor (TNF) and prostaglandin E2 (PGE) by peripheral blood mononuclear cells (PBMC). These three mediators show potent bone-resorbing activity. However, we did not find any significant effect of pharmacological concentrations of PTH or calcitonin on the secretion of IL-1, TNF or PGE by PBMC.

Adult↗

Effect of physiological concentrations of calcitriol on lymphocyte proliferation in normal subjects and in patients with renal failure.

Specific receptors for calcitriol (1,25-dihydroxyvitamin D) have been found in immune cells, such as monocytes and activated lymphocytes, suggesting that calcitriol may play an immunoregulatory role. In fact, a marked increase in lymphocyte proliferation has been reported after treating hemodialyzed patients with 1 alpha-hydroxyvitamin D3, a precursor of calcitriol. We have studied in vitro the effect of calcitriol depletion and calcitriol addition on the phytohemagglutinin-induced mitogenesis of peripheral blood mononuclear cells from 14 healthy subjects and 8 hemodialyzed patients. The calcitriol depletion of culture medium did not modify cell proliferation. The addition of calcitriol in concentrations about the physiological range (10(-11) M) induced a small, marginally significant, 11% increase in the proliferation of lymphocytes from hemodialysis patients. Supraphysiological concentrations (10(-9)-10(-7) M) induced a marked inhibition (up to 60% of control values) of cell mitogenesis, both in patients and in healthy subjects. These results suggest that the increase in lymphocyte proliferation observed in vivo after treatment with calcitriol precursors is not mediated by a direct effect of calcitriol on circulating mononuclear cells.

Adult↗

Role of monocytes in the inhibitory effect of calcitriol on PHA-stimulated lymphocytes.

The possible role played by monocytes in the inhibitory effect of calcitriol on phytohemagglutinin (PHA)-stimulated lymphocyte proliferation was assessed by testing the effect of this sterol under different cell culture conditions. Calcitriol had a dose-dependent inhibitory effect on lymphocyte proliferation in concentrations ranging from 10(-10) up to 10(-8) M. The effect of 10(-9) M calcitriol was almost completely abolished by: a) monocyte depletion, b) inhibition of prostaglandin (PG) synthesis by indomethacin, and c) addition of exogenous interleukin-2 (IL-2). These results suggested that the inhibitory effect of calcitriol was mediated through monocytes. This possibility was substantiated by the following observations: a) the calcitriol inhibitory effect was restored when autologous adherent cells were added to monocyte-depleted PBM cells; b) the supernatant of adherent cells cultured for 24 hours in the presence of calcitriol exerted a marked inhibitory effect on lymphocyte proliferation; and c) this effect was not longer evident when adherent cells were cultured in the presence of calcitriol plus indomethacin. These data support the hypothesis that calcitriol acts, at least partially, through the monocytes, inducing an increased release of PG, with subsequent inhibition of IL-2 synthesis, then resulting in a decreased lymphocyte proliferation.

Calcitriol↗

T and B cell function in psoriasis and psoriatic arthropathy.

The pathogenetic mechanisms of psoriasis and psoriatic arthropathy (PsA) are not completely known. Previous studies have suggested the participation of the immune system in this process. In this work we have analyzed several aspects of B and T cells function in peripheral blood of 40 patients with psoriasis (age 44 +/- 15 yr.). Twenty-eight of them had PsA. As a control group we studied 35 healthy subjects aged 36 +/- 14 yr. The B cell function was evaluated through the following tests: a) Serum immunoglobulin (Ig's) levels; b) Number of circulating IgA-, IgG- and IgM-secreting cells; c) Ig's-secreting cells after PWM stimulation; and d) Response to autologous mixed lymphocyte reaction. To evaluate the T cell function, we studied the response to PHA stimulation and its modification by the inhibition of prostaglandin synthesis with indomethacin. In the group of patients, we observed the following abnormalities: a) A significant increase in serum levels of IgG (1,170 +/- 363 mg/dl in patients versus 885 +/- 167 mg/dl in controls, p less than 0.01) and IgA (250 +/- 143 versus 154 +/- 38 mg/dl, p less than 0.05); b) A decreased response of B lymphocytes to PWM, statistically significant for the number of cells secreting every type of Ig's (p less than 0.001); and c) An impaired response to PHA (47,755 +/- 23,129 cpm in patients versus 73,634 +/- 31,085 cpm in controls, p less than 0.001), that partially improved (34% of enhancement) after inhibition of prostaglandin synthesis with indomethacin.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗